Business Context and Reporting Period
This Form 8-K is a Current Report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on November 15, 2022. The registrant is a Delaware corporation with principal executive offices in Palo Alto, California, and its common stock trades on the NASDAQ under the symbol ATNF. The filing serves as a Regulation FD disclosure regarding new research findings related to the company's therapeutic candidates.
Key Financial Metrics
This filing is a current report regarding a specific event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial data is contained within this document.
Material Changes
The material event reported is the issuance of a press release on November 15, 2022, announcing research findings by Oxford Population Health's Health Economics Research Centre and the Kennedy Institute of Rheumatology. The research suggests that anti-tumor necrosis factor (TNF) treatment (adalimumab), commonly used for rheumatoid arthritis and psoriasis, is likely to be a cost-effective treatment for people affected by early-stage Dupuytren's disease.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The press release furnished as Exhibit 99.1 contains forward-looking statements subject to risks, uncertainties, and assumptions. Actual results may differ materially from projections.
- Risk Factors: The filing references standard risk factors regarding the company's financial results and business trends, directing investors to the "Risk Factors" and "Management's Discussion and Analysis" sections of periodic filings (10-Q and 10-K) for detailed information.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated.
Investor Verification Checklist
- Verify the specific details of the research study regarding adalimumab and Dupuytren's disease in the press release attached as Exhibit 99.1.
- Review the company's most recent Form 10-Q or 10-K for actual financial performance, cash position, and liquidity status, as this 8-K contains no financial data.
- Confirm the regulatory status and development timeline of the company's pipeline related to the announced research findings.
- Note the discrepancy between the request metadata (Forum Markets Inc.) and the actual filing registrant (180 Life Sciences Corp.).